Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

医学 伦瓦提尼 彭布罗利珠单抗 头颈部鳞状细胞癌 肿瘤科 内科学 头颈部癌 头颈部 外科 免疫疗法 放射治疗 癌症 甲状腺癌
作者
Lisa Licitra,Makoto Tahara,Kevin J. Harrington,Mivael Olivera,Yi Guo,Sercan Aksoy,Min Fang,Bogdan Żurawski,Tibor Csöszi,Mikhail Klochikhin,Tainá B. Oliveira,Shunji Takahashi,Muh‐Hwa Yang,Paul Swiecicki,Karen O’Hara,John Paul Shen,Andrew Z. Wang,Burak Gümüşçü,K.C. Benjamin,Robert I. Haddad
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:118 (5): e2-e3 被引量:10
标识
DOI:10.1016/j.ijrobp.2024.01.016
摘要

Purpose/Objective(s) The PD-1 inhibitor pembrolizumab (pembro) is approved as first-line monotherapy for patients (pts) with PD-L1-expressing R/M HNSCC (PD-L1 combined positivity score [CPS] ≥1). A phase 1b/2 study of pembro plus the multikinase inhibitor lenvatinib (len) showed promising antitumor activity and manageable toxicity in pts with HNSCC. In LEAP-010, a phase 3, randomized, placebo-controlled, double-blind study, we hypothesized that first-line len + pembro would improve efficacy compared with placebo + pembro, and have a manageable safety profile, in pts with PD-L1 CPS ≥1 R/M HNSCC (NCT04199104). Materials/Methods Eligible pts had R/M HNSCC incurable by local therapy, PD-L1 CPS ≥1 by central laboratory assessment, known HPV status, and ECOG PS 0 or 1. Pts were randomized 1:1 to len 20 mg or placebo orally once daily plus pembro 200 mg IV Q3W for ≤35 cycles given until intolerable toxicity, progression, or withdrawal. Primary end points were ORR and PFS per RECIST 1.1 by BICR and OS; secondary end points were DOR per RECIST 1.1 by BICR and safety. Per the prespecified analysis plan, ORR and PFS are reported from the first interim analysis (IA1) and OS and DOR are reported from IA2. Data cutoff dates were July 6, 2022 for IA1 and May 30, 2023 for IA2. Results 511 pts were randomized to len + pembro (n = 256) or placebo + pembro (n = 255). Median follow-up (ie, time from randomization to data cutoff) was 11.5 months (mo; range, 0.0-27.6) for IA1 and 21.3 mo (range, 9.0-38.4) for IA2. At IA1, median PFS was 6.2 mo (95% CI: 5.1-7.2) for len + pembro vs 2.8 mo (95% CI: 2.0-4.0) for placebo + pembro (HR: 0.64, 95% CI: 0.50-0.81; P=0.0001040). At IA1 and among the 351 pts with ≥6-mo follow-up, ORR was 46.1% (95% CI: 38.6-53.7) for len + pembro vs 25.4% (95% CI: 19.1-32.6) for placebo + pembro (difference 20.2, 95% CI 10.5-29.6, P=0.0000251). At IA2, median DOR was 10.1 mo (range, 1.3-30.9) for len + pembro vs NR (1.2-32.2) for placebo + pembro. At IA2, the median OS was 15.0 mo (95% CI: 13.2-17.0) for len + pembro vs 17.9 mo (95% CI: 13.8-21.6) for placebo + pembro (HR = 1.15, 95% CI: 0.91-1.45; P=0.882), with respective 24-month OS of 35.7% (95% CI: 29.0-42.4) and 40.0% (95% CI: 32.8-47.1). At IA2, 156 (61.4%) pts on len + pembro had grade ≥3 treatment-related adverse events (TRAEs) vs 45 (17.8%) on placebo + pembro, 28% vs 8% pts discontinued any treatment due to TRAEs, and 7 vs 3 pts had treatment-related deaths, respectively. Conclusion In pts with PD-L1 CPS ≥1 R/M HNSCC, first-line len + pembro significantly improved PFS and ORR, but not OS, compared with pembro alone. The safety profile was consistent with previously reported data; more TRAEs were found in pts receiving len + pembro. Further research is needed to identify effective treatment options for these pts. The PD-1 inhibitor pembrolizumab (pembro) is approved as first-line monotherapy for patients (pts) with PD-L1-expressing R/M HNSCC (PD-L1 combined positivity score [CPS] ≥1). A phase 1b/2 study of pembro plus the multikinase inhibitor lenvatinib (len) showed promising antitumor activity and manageable toxicity in pts with HNSCC. In LEAP-010, a phase 3, randomized, placebo-controlled, double-blind study, we hypothesized that first-line len + pembro would improve efficacy compared with placebo + pembro, and have a manageable safety profile, in pts with PD-L1 CPS ≥1 R/M HNSCC (NCT04199104). Eligible pts had R/M HNSCC incurable by local therapy, PD-L1 CPS ≥1 by central laboratory assessment, known HPV status, and ECOG PS 0 or 1. Pts were randomized 1:1 to len 20 mg or placebo orally once daily plus pembro 200 mg IV Q3W for ≤35 cycles given until intolerable toxicity, progression, or withdrawal. Primary end points were ORR and PFS per RECIST 1.1 by BICR and OS; secondary end points were DOR per RECIST 1.1 by BICR and safety. Per the prespecified analysis plan, ORR and PFS are reported from the first interim analysis (IA1) and OS and DOR are reported from IA2. Data cutoff dates were July 6, 2022 for IA1 and May 30, 2023 for IA2. 511 pts were randomized to len + pembro (n = 256) or placebo + pembro (n = 255). Median follow-up (ie, time from randomization to data cutoff) was 11.5 months (mo; range, 0.0-27.6) for IA1 and 21.3 mo (range, 9.0-38.4) for IA2. At IA1, median PFS was 6.2 mo (95% CI: 5.1-7.2) for len + pembro vs 2.8 mo (95% CI: 2.0-4.0) for placebo + pembro (HR: 0.64, 95% CI: 0.50-0.81; P=0.0001040). At IA1 and among the 351 pts with ≥6-mo follow-up, ORR was 46.1% (95% CI: 38.6-53.7) for len + pembro vs 25.4% (95% CI: 19.1-32.6) for placebo + pembro (difference 20.2, 95% CI 10.5-29.6, P=0.0000251). At IA2, median DOR was 10.1 mo (range, 1.3-30.9) for len + pembro vs NR (1.2-32.2) for placebo + pembro. At IA2, the median OS was 15.0 mo (95% CI: 13.2-17.0) for len + pembro vs 17.9 mo (95% CI: 13.8-21.6) for placebo + pembro (HR = 1.15, 95% CI: 0.91-1.45; P=0.882), with respective 24-month OS of 35.7% (95% CI: 29.0-42.4) and 40.0% (95% CI: 32.8-47.1). At IA2, 156 (61.4%) pts on len + pembro had grade ≥3 treatment-related adverse events (TRAEs) vs 45 (17.8%) on placebo + pembro, 28% vs 8% pts discontinued any treatment due to TRAEs, and 7 vs 3 pts had treatment-related deaths, respectively. In pts with PD-L1 CPS ≥1 R/M HNSCC, first-line len + pembro significantly improved PFS and ORR, but not OS, compared with pembro alone. The safety profile was consistent with previously reported data; more TRAEs were found in pts receiving len + pembro. Further research is needed to identify effective treatment options for these pts.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
韩麒嘉完成签到 ,获得积分10
2秒前
聪慧的凝海完成签到 ,获得积分0
11秒前
11秒前
wwb发布了新的文献求助10
14秒前
phil完成签到 ,获得积分10
14秒前
22秒前
高高菠萝完成签到 ,获得积分10
22秒前
滴滴滴完成签到 ,获得积分10
22秒前
yangsi完成签到 ,获得积分10
25秒前
量子星尘发布了新的文献求助10
26秒前
29秒前
酷炫葵阴发布了新的文献求助10
34秒前
ORANGE完成签到,获得积分10
36秒前
思源应助松松采纳,获得20
40秒前
共享精神应助酷炫葵阴采纳,获得10
42秒前
丝丢皮得完成签到 ,获得积分10
43秒前
44秒前
xfy完成签到,获得积分10
48秒前
阳炎完成签到,获得积分10
50秒前
行云流水完成签到,获得积分10
51秒前
52秒前
冷酷尔琴发布了新的文献求助10
56秒前
青水完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
冷酷尔琴完成签到,获得积分10
1分钟前
onevip完成签到,获得积分0
1分钟前
小莫完成签到 ,获得积分10
1分钟前
1分钟前
theseus完成签到,获得积分10
1分钟前
胡楠完成签到,获得积分10
1分钟前
北国雪未消完成签到 ,获得积分10
1分钟前
李振博完成签到 ,获得积分10
1分钟前
1分钟前
雪妮完成签到 ,获得积分10
1分钟前
松松发布了新的文献求助20
1分钟前
1分钟前
iwsaml完成签到 ,获得积分10
1分钟前
Caden完成签到 ,获得积分10
1分钟前
xmhxpz完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038029
求助须知:如何正确求助?哪些是违规求助? 3575740
关于积分的说明 11373751
捐赠科研通 3305559
什么是DOI,文献DOI怎么找? 1819224
邀请新用户注册赠送积分活动 892652
科研通“疑难数据库(出版商)”最低求助积分说明 815022